To find out if there are one or more criteria to guide selection among the ACE inhibitors for the treatment of arterial hypertension, we have reviewed the principal pharmacokinetic and pharmacodynamic aspects of the more frequently used agents of this class of antihypertensive drugs.
Among the pharmacokinetic aspects that we have considered, terminal halflife, as related to the duration of the antihypertensive effect, and the route of elimination may have an impact in the clinical selection among the various ACE inhibitors.
On the other band, all the other characteristics have no pragmatic clinical relevance or may be corrected by dosage adjustment.
Among the pharmacodynamic aspects, the antihypertensive efficacy of the different ACE inhibitors seems to be very similar, and some of the differences found in different studies are probably due to the population investigated and to the protocol of the study (time of blood pressure measurements, diet, drug dosage etc.). However, some differences can be found among the various ACE inhibitors, when the antihypertensive efficacy is evaluated also as through to peak ratio of blood pressure reduction.
Mots-clés Pascal : Homme, Qualité vie, Hypertension artérielle, Chimiothérapie, Traitement, Pharmacocinétique, Hémodynamique, Antihypertenseur, Pression artérielle, Article synthèse, Choix, Activité biologique, Appareil circulatoire pathologie, Inhibiteur angiotensin converting enzyme, Ajustement posologie
Mots-clés Pascal anglais : Human, Quality of life, Hypertension, Chemotherapy, Treatment, Pharmacokinetics, Hemodynamics, Antihypertensive agent, Arterial pressure, Review, Choice, Biological activity, Cardiovascular disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0188579
Code Inist : 002B02F05. Création : 09/06/1995.